Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 10/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019287 | 0.99 | EGFR (0.59) | EGFRBTKTOP2ACSNK2A2CSNK2B | |
| SCHEMBL12635826 | 0.91 | BTK (0.56) | EGFRBTKTOP2ABRAFTNNI3K | |
| SCHEMBL2022001 | 0.90 | BTK (0.60) | BTKBRAFTNNI3K | |
| SCHEMBL2024535 | 0.90 | BTK (0.64) | BTK | |
| SCHEMBL2018889 | 0.89 | BTK (0.54) | EGFRBTKBRAFTNNI3K | |
| SCHEMBL2019641 | 0.89 | BTK (0.60) | EGFRBTKBRAFTNNI3K | |
| Lithium Ion SCHEMBL2019675 | 0.89 | BTK (0.54) | EGFRBTKTOP2ABRAFTNNI3K | |
| SCHEMBL12493140 | 0.89 | BTK (0.56) | EGFRBTKBRAFTNNI3K | |
| SCHEMBL2018674 | 0.88 | BTK (0.55) | EGFRBTKBRAFTNNI3K | |
| SCHEMBL2018256 | 0.88 | BTK (0.55) | EGFRBTKBRAFTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580803-B2 | Substituted pyrrolo-aminopyrimidine compounds | ARQULE, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2519525-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082273-A2 | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160203-A1 | Substituted Pyrrolo-Aminopyrimidine Compounds | DPYD, TYMP, DHFR | EGFR 1215/4885BTK 1600/4885TOP2A 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.